Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Aroldi · SciRah

Researcher profile · Semantic Scholar

A. Aroldi

Share profile

A. Aroldi — researcher profile on SciRah

h-index: 14
Works: 54
Citations: 438

Most-cited papers

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
Elisa Bergaggio, Wei-Tien Tai, A. Aroldi, Carmen Mecca +17 more
2023Cancer Cell53 citations Open access
Semantic Scholar
Chronic myeloid leukemia: Second‐line drugs of choice
C. Gambacorti-Passerini, A. Aroldi, N. Cordani, R. Piazza
2016American journal of hematology/oncology38 citations Open access
Semantic Scholar
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
E. Bossi, A. Aroldi, F. Brioschi, Carolin Steidl +9 more
2020American journal of hematology/oncology36 citations Open access
Semantic Scholar
Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
M. Clerico, I. Dogliotti, A. Aroldi, C. Consoli +3 more
2022Journal of Clinical Medicine25 citations Open access
Semantic Scholar
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
Elena Inzoli, A. Aroldi, R. Piazza, C. Gambacorti-Passerini
2022American journal of hematology/oncology23 citations Open access
Semantic Scholar
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas
Giovanni Rindone, A. Aroldi, E. Bossi, L. Verga +6 more
2022Blood Advances22 citations Open access
Semantic Scholar
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
D. Fontana, Daniele Ramazzotti, A. Aroldi, S. Redaelli +26 more
2020HemaSphere21 citations Open access
Semantic Scholar
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors
F. Boccalatte, Roberto Mina, A. Aroldi, S. Leone +3 more
2022Cancers19 citations Open access
Semantic Scholar
Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
E. Elli, A. Belotti, A. Aroldi, M. Parma +2 more
2014Mediterranean Journal of Hematology and Infectious Diseases19 citations Open access
Semantic Scholar
Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia
A. Aroldi, Mario Mauri, Daniele Ramazzotti, M. Villa +12 more
2023Journal of Cellular and Molecular Medicine18 citations Open access
Semantic Scholar
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer
Valentina Crippa, N. Cordani, A. Villa, F. Malighetti +7 more
2025npj Precision Oncology15 citations Open access
Semantic Scholar
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision‐making
I. Civettini, Arianna Zappaterra, Bianca Maria Granelli, Giovanni Rindone +11 more
2023British Journal of Haematology15 citations Open access
Semantic Scholar
Treatment of Philadelphia‐negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors
A. Andriani, E. Elli, G. Trapè, Nicoletta Villiva' +14 more
2019Hematological Oncology15 citations
Semantic Scholar
CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma
A. Aroldi, Mario Mauri, M. Parma, E. Terruzzi +7 more
2021Blood14 citations Open access
Semantic Scholar
Deferasirox in the management of iron‐overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON‐M study)
E. Elli, A. Iurlo, A. Aroldi, M. Caramella +13 more
2019British Journal of Haematology13 citations Open access
Semantic Scholar
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study
M. Farina, S. Bernardi, M. Malagola, Alessandro Re +20 more
2025Bone Marrow Transplantation12 citations Open access
Semantic Scholar
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
D. Fontana, I. Crespiatico, Valentina Crippa, F. Malighetti +10 more
2023bioRxiv12 citations Open access
Semantic Scholar
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
I. Crespiatico, M. Zaghi, C. Mastini, D. D’Aliberti +36 more
2023Blood11 citations Open access
Semantic Scholar
Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy
A. Aroldi, C. Cecchetti, Arianna Colombo, L. Cattaneo +3 more
2016European Journal of Haematology10 citations
Semantic Scholar
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
Rossella Renso, A. Aroldi, P. Pioltelli, C. Gambacorti-Passerini +1 more
2018Blood Cancer Journal8 citations Open access
Semantic Scholar
Idiopathic erythrocytosis: a germline disease?
E. Elli, M. Mauri, D. D’Aliberti, I. Crespiatico +17 more
2024Clinical and Experimental Medicine (Testo stampato)6 citations Open access
Semantic Scholar
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
M. Villa, G. Cazzaniga, M. Bolognesi, F. Malighetti +7 more
2025Heliyon5 citations Open access
Semantic Scholar
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy
B. Manghisi, Giulia Cotilli, M. Fedele, Paola Perfetti +21 more
2025Frontiers in Immunology5 citations Open access
Semantic Scholar
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis
F. Malighetti, M. Villa, A. Villa, S. Pelucchi +8 more
2025International Journal of Molecular Sciences4 citations Open access
Semantic Scholar
Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months
S. Mori, P. le Coutre, E. Abruzzese, B. Martino +19 more
20154 citations
Semantic Scholar
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
C. Gambacorti-Passerini, M. Ruggeri, A. Aroldi, R. Piazza +4 more
2021Transfusion and Apheresis Science3 citations Open access
Semantic Scholar
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
F. Malighetti, M. Villa, Mario Mauri, Simone Piane +12 more
2024Biomedicines2 citations Open access
Semantic Scholar
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
C. Gambacorti-Passerini, F. Nicolini, R. Larson, A. Aroldi +5 more
2022American journal of hematology/oncology2 citations Open access
Semantic Scholar
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples
A. Aroldi, Fabrizio Angaroni, D. D’Aliberti, S. Spinelli +5 more
2022Viruses2 citations Open access
Semantic Scholar
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.
I. Civettini, F. Malighetti, M. Villa, Valentina Crippa +25 more
2026NEJM Evidence1 citations
Semantic Scholar
Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models
M. Villa, F. Malighetti, A. Villa, N. Cordani +4 more
2026Journal of Translational Medicine1 citations Open access
Semantic Scholar
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer
Valentina Crippa, N. Cordani, A. Villa, F. Malighetti +7 more
2025npj Precision Oncology1 citations Open access
Semantic Scholar
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors
M. Villa, F. Malighetti, Luca De Sano, A. Villa +8 more
2025Nucleic Acids Research1 citations Open access
Semantic Scholar
Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors: 5-Year Update of a Phase 2 Open Label Monocentric Study
Federica Colombo, A. Aroldi, Stefano Crippa, F. Cocito +5 more
2024Blood1 citations
Semantic Scholar
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype.
I. Civettini, Arianna Zappaterra, Paola Corti, Amedeo Messina +14 more
2024i Medicina1 citations
Semantic Scholar
Preliminary Results of Phase 2 Open Label Study of Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors
A. Ripamonti, A. Aroldi, F. Cocito, L. Guerra +4 more
2023Blood1 citations Open access
Semantic Scholar
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
E. Bossi, A. Aroldi, L. Borin, L. Verga +13 more
2022eJHaem1 citations Open access
Semantic Scholar
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
A. Aroldi, R. Chiarle, C. Gambacorti-Passerini
2021Mayo Clinic proceedings1 citations Open access
Semantic Scholar
Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations
F. Malighetti, I. Civettini, A. Aroldi, A. Villa +8 more
2026Bioinformatics0 citations Open access
Semantic Scholar
Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience
F. Bonello, A. Aroldi, A. Castellino, L. Mannelli +4 more
2026European Journal of Haematology0 citations Open access
Semantic Scholar
Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation
G. Orofino, I. Sánchez-Ortega, Juan Mota, A. Aroldi +35 more
2026EClinicalMedicine0 citations Open access
Semantic Scholar
Lorlatinib therapy in relapsed/refractory ALK+ lymphomas previously treated with tyrosine kinase inhibitors.
Federica Colombo, A. Aroldi, Stefano Crippa, F. Cocito +5 more
2025Journal of Clinical Oncology0 citations Open access
Semantic Scholar
Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach
I. Civettini, F. Malighetti, M. Villa, Valentina Crippa +25 more
2025Blood0 citations
Semantic Scholar
Abstract 50: ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
Elisa Bergaggio, Wei-Tien Tai, A. Aroldi, Carmen Mecca +17 more
2024Cancer Research0 citations
Semantic Scholar
Abstract 861: Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
M. Villa, G. Cazzaniga, M. Bolognesi, Valentina Crippa +7 more
2024Cancer Research0 citations
Semantic Scholar
Abstract 6208: Characterization of molecular evolution in myelodysplastic neoplasms
I. Civettini, Valentina Crippa, F. Malighetti, M. Villa +8 more
2024Cancer Research0 citations
Semantic Scholar
Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study
M. Farina, Eugenio Galli, M. Riva, I. Cutini +19 more
2024Blood0 citations
Semantic Scholar
Hemoglobin Monza: A New Variant of Unstable Hemoglobin
I. Civettini, Paola Corti, Arianna Zappaterra, Amedeo Messina +12 more
2023Blood0 citations Open access
Semantic Scholar
Targeting CD24 “Don't Eat Me” Signal Restores Phagocytic Activity of Nurse-like Cells from Patients with Chronic Lymphocytic Leukemia
A. Aroldi, Mario Mauri, D. Ramazzotti, Simone Piane +9 more
2023Blood0 citations Open access
Semantic Scholar
Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma
A. Aroldi, Mario Mauri, M. Villa, F. Malighetti +6 more
2022Blood0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Mologni×21
Invite
L. Mologni — researcher profile on SciRah
F. Malighetti×17
Invite
F. Malighetti — researcher profile on SciRah
D. Ramazzotti×17
Invite
D. Ramazzotti — researcher profile on SciRah
M. Villa×16
Invite
M. Villa — researcher profile on SciRah

C. Gambacorti-Passerini

×15

Invite

C. Gambacorti-Passerini — researcher profile on SciRah

Invite

R. Piazza — researcher profile on SciRah

Valentina Crippa×13

Invite

Valentina Crippa — researcher profile on SciRah

C. Gambacorti-Passerini×12

Invite

C. Gambacorti-Passerini — researcher profile on SciRah

Invite

R. Piazza — researcher profile on SciRah

I. Civettini×9

Invite

I. Civettini — researcher profile on SciRah

Invite

R. Chiarle — researcher profile on SciRah

Invite

E. Elli — researcher profile on SciRah